Literature DB >> 7528996

Enhanced pulmonary arterial dilation to arginine vasopressin in chronically hypoxic rats.

M R Eichinger1, B R Walker.   

Abstract

Chronic hypoxic exposure elicits pulmonary vascular remodeling and may alter normal pulmonary endothelial function. We examined the vasodilatory response to the receptor-mediated endothelium-dependent dilator arginine vasopressin (AVP), the non-receptor-mediated endothelium-dependent dilator A-23187, and the nitric oxide (NO) donor sodium nitroprusside in lungs isolated from control or chronically hypoxic rats. Lungs were isolated from male Sprague-Dawley rats and perfused with a physiological saline solution containing 4% albumin. Arterial and venous pressures were monitored and microvascular pressure was estimated by double occlusion, allowing assessment of segmental resistances. After equilibration, lungs were constricted with the thromboxane mimetic U-46619. Upon development of a stable pressor response, lungs were dilated with one of the above agents. A series of doses of AVP was administered to separate groups of lungs from control or chronically hypoxic rats. Lungs from chronically hypoxic rats exhibited an augmented dilatory response to AVP compared with control lungs, and this effect was due to enhanced dilation of precapillary segments. The total and segmental vasodilatory responses to A-23187 and sodium nitroprusside were not different between the two groups of lungs, suggesting that chronic hypoxia did not upregulate the enzyme NO synthase or enhance the vascular smooth muscle responsiveness to NO. Thus our data suggest that the augmented total and pulmonary arterial dilation to AVP after chronic hypoxia is most likely due to altered receptor-mediated processes of the hormone.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7528996     DOI: 10.1152/ajpheart.1994.267.6.H2413

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

1.  Enhanced NO-dependent pulmonary vasodilation limits increased vasoconstrictor sensitivity in neonatal chronic hypoxia.

Authors:  Joshua R Sheak; Laura Weise-Cross; Ray J deKay; Benjimen R Walker; Nikki L Jernigan; Thomas C Resta
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-07-21       Impact factor: 4.733

Review 2.  Management of acute right ventricular failure in the intensive care unit.

Authors:  Eric M Green; Michael M Givertz
Journal:  Curr Heart Fail Rep       Date:  2012-09

Review 3.  Management of vasodilatory shock: defining the role of arginine vasopressin.

Authors:  Martin W Dunser; Volker Wenzel; Andreas J Mayr; Walter R Hasibeder
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  [Vasopressin as a rescue vasopressor agent. Treatment of selected cardiogenic shock states].

Authors:  V D Mayr; G Luckner; S Jochberger; V Wenzel; W R Hasibeder; M W Dünser
Journal:  Anaesthesist       Date:  2007-10       Impact factor: 1.041

Review 5.  Vasopressin vs. terlipressin in the treatment of cardiovascular failure in sepsis.

Authors:  Matthias Lange; Christian Ertmer; Martin Westphal
Journal:  Intensive Care Med       Date:  2007-12-08       Impact factor: 17.440

Review 6.  Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review.

Authors:  Laura C Price; Stephen J Wort; Simon J Finney; Philip S Marino; Stephen J Brett
Journal:  Crit Care       Date:  2010-09-21       Impact factor: 9.097

Review 7.  Clinical review: Vasopressin and terlipressin in septic shock patients.

Authors:  Anne Delmas; Marc Leone; Sébastien Rousseau; Jacques Albanèse; Claude Martin
Journal:  Crit Care       Date:  2004-09-09       Impact factor: 9.097

8.  Vasopressin vs Terlipressin in Treatment of Refractory Shock.

Authors:  G Scarpati; O Piazza
Journal:  Transl Med UniSa       Date:  2013-01-04

9.  Age dependency of vasopressin pulmonary vasodilatory effect in rats.

Authors:  Masahiro Enomoto; Jingyi Pan; Yulia Shifrin; Jaques Belik
Journal:  Pediatr Res       Date:  2013-11-20       Impact factor: 3.756

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.